Burden of Disease; the Current Status of the Diagnosis and Management of Atopic Dermatitis in China

Atopic dermatitis (AD) is now a global health problem and has been attracting extensive attention from both academic and public society in China. This review aimed to present the current status of the prevalence, disease burden, clinical features, diagnosis, and management of AD in China. The prevalence of AD has been increasing rapidly in China during the past decades, partially due to the increased recognition of the disease; there are still substantial amounts of over-diagnosed eczema and under-diagnosed AD. Chinese dermatologists see many AD patients with atypical manifestation, which poses a challenge to the diagnosis. The Chinese diagnostic criteria for adults and pediatric patients with AD have been proposed respectively and validated with high sensitivity and specificity. International and Chinese guidelines for management of AD have been popularized; however, there are still many practices that need verification through randomized case-control study. Dupilumab and JAK inhibitors have demonstrated favorable efficacy for AD patients in China, and a multidimensional approach is needed for selection of the patients and evaluation of the efficacy and safety. Patient education and long-term management for AD are just beginning in China, and need to be strengthened in the future.

Automated summary

This review presents the current status of atopic dermatitis (AD) in China, including prevalence, disease burden, clinical features, diagnosis, and management. The prevalence of AD has been increasing rapidly in China, but there are still significant amounts of over-diagnosed eczema and under-diagnosed AD. Chinese dermatologists face challenges in diagnosing AD due to atypical manifestations. Chinese diagnostic criteria have been proposed and validated with high sensitivity and specificity. Dupilumab and JAK inhibitors have shown favorable efficacy for AD patients in China, but patient education and long-term management still need improvement.